Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective
作者: Eleonora AielloPablo Manuel BianculliDevarshi BhattacharyyaPraveen GundaGustavo Citera
作者单位: 1Independent Consultant, Buenos Aires, Argentina
2Novartis Argentina SA, Buenos Aires, Argentina
3Novartis Healthcare Private Limited, Hyderabad, India
4Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
刊名: Value in Health Regional Issues, 2019, Vol.20 , pp.86-94
来源数据库: Elsevier Journal
DOI: 10.1016/j.vhri.2019.03.002
关键词: SecukinumabPsoriatic arthritisCost-effectivenessArgentinaInterleukin-17A inhibitorTumor necrosis factor inhibitorsIncremental cost-effectiveness ratioQuality-adjusted life year
英文摘要: Abstract(#br)Objective(#br)Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease. This study assessed the cost-effectiveness of secukinumab, an interleukin-17A inhibitor, versus other biologics in PsA from the Argentinean social security perspective.(#br)Methods(#br)A semi-Markov model evaluated subcutaneous (sc) treatment with secukinumab 150 mg and 300 mg against other sc treatments such as adalimumab, certolizumab pegol, etanercept, golimumab, ustekinumab, and intravenous treatment infliximab in biologic-naïve (with or without moderate to severe psoriasis) and biologic-experienced PsA patients over a lifetime horizon. Response to treatments was determined using the PsA Response Criteria (PsARC) at 12 weeks. Model inputs were derived from randomized controlled trials,...
全文获取路径: Elsevier  (合作)
分享到:

×